INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud by AMAG Pharmaceuticals, Inc. and Certain Officers and Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of AMAG Pharmaceuticals, Inc. (“AMAG Pharmaceuticals” or the “Company”) (NASDAQGS: AMAG) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On November 18, 2015, AMAG Pharmaceuticals disclosed the receipt of a Complete Response Letter from the U.S. Food and Drug Administration for its application seeking approval for a single-dose vial of Makena to reduce the risk of preterm birth in certain at-risk patients. This is the second such letter from the FDA this year. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/amag-pharmaceuticals-amag

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151119006793/en/